Sourcing & Quality

How to Source Peptides You Can Trust

A clinical buyer's framework for evaluating compounding pharmacies, reading Certificates of Analysis, and explaining the “Research Use Only” label to patients.

Last updated: April 21, 2026
Important Disclaimer: This content is educational and does not endorse any specific supplier, pharmacy, or product. Verify regulatory posture, licensure, and lot-specific quality directly with the supplier and with FDA and state sources. Consult legal counsel for procurement decisions.

The framework

Five Questions to Answer Before You Commit to a Supplier

Sourcing is the most frequently cited unsolved problem in peptide practice. Run a new supplier through these five questions before your first order. Each unanswered question is a risk that shows up later as a compliance issue, an unhappy patient, or expired inventory.

  1. 1

    Is it US-made?

    US-based manufacturing places the product under FDA jurisdiction and generally correlates with tighter process controls. Verify the manufacturing site directly — not just the distributor headquarters.

  2. 2

    503A, 503B, or Research-Chemical Vendor?

    These are three different regulatory regimes with different labeling, liability, and what you can say to patients. Know which one applies to every SKU before you order.

  3. 3

    Can the Supplier Produce a Lot-Specific COA?

    A legitimate Certificate of Analysis is lot-specific and includes identity, purity (by HPLC), mass-spec identity confirmation, and endotoxin testing. Generic COAs repeated across shipments are a red flag.

  4. 4

    Lyophilized Powder or Pre-Reconstituted Solution?

    Lyophilized products often carry 12+ month shelf life. Pre-reconstituted solutions can expire in as little as 3 months — a real inventory risk if you cannot move the stock.

  5. 5

    Do the Wholesale Unit Economics Work?

    Benchmark your wholesale cost against publicly available retail pricing that patients can find. If your cost already exceeds common retail, the business math will not support a sustainable cash practice.

Printable Source-Vetting Checklist

A 10-question checklist your team can run through in a single pass with a new supplier. Includes signature and notes section for documentation.

Download checklist

Certificates of Analysis

How to Read a COA Without Hand-Waving

Patients increasingly ask for a Certificate of Analysis by name. The fields below are the minimum bar for any peptide COA, with a sample entry and a plain-language explanation of why each one matters.

What a Legitimate COA Should Include

A Certificate of Analysis is the supplier's written quality attestation for a specific lot. Patients and prescribers increasingly ask for one by name. Use the fields below as a minimum bar when reviewing any peptide COA.

Product identity
BPC-157 acetate, lyophilized powder
Confirms what is actually in the vial. Should match the peptide you ordered exactly, including salt form (acetate vs trifluoroacetate).
Batch / lot number
Lot #BPC240318-A
Traceable to a specific production run. Required to investigate any adverse event and to verify stability testing.
Purity (HPLC)
≥ 99.2% by HPLC-UV at 220 nm
The percentage of the sample that is the intended peptide. Clinical-grade peptides should be ≥ 98%; research-grade may be lower.
Identity confirmation
Mass spec (MS): observed 1420.6 Da; theoretical 1419.5 Da
An orthogonal test that verifies molecular weight. Catches substitutions and degradation products that HPLC alone can miss.
Endotoxin
< 0.5 EU/mg by LAL
Bacterial endotoxin load. Critical for any injectable product. USP sets limits; values above threshold can cause febrile reactions.
Sterility (for sterile preparations)
USP <71> sterility test: passes
Required for any compounded sterile injectable. A COA for a non-sterile bulk powder will not include this — that is acceptable, but the end preparation must be tested.
Manufacturer / testing lab
Manufactured in the United States; tested at [third-party lab]
Geography matters for regulatory posture. Third-party testing (vs. in-house only) is a stronger quality signal.
Date of manufacture and retest
Manufactured 2026-02-01; retest by 2028-02-01
Establishes stability window. A COA with no dates or a retest date in the past is unusable.

Red Flags on a COA

  • Supplier cannot or will not produce a COA for the specific lot shipped.
  • COA is generic — no batch/lot number, or the same COA is reused across multiple shipments.
  • Purity is reported without the method (HPLC vs. TLC vs. unspecified). "Pharmaceutical grade" alone is not a COA claim.
  • No identity confirmation by mass spec or equivalent — HPLC alone can miss substitutions.
  • No endotoxin or sterility testing on an injectable product.
  • Testing lab is a subsidiary of the manufacturer with no third-party verification.
  • Dates are missing, stale, or in the future (a manufacture date of next month is a fabrication tell).

Patient counseling

The “Research Use Only” Label Problem

Patients regularly see “For Research Use Only” or “Not For Human Consumption” printed on a peptide vial and assume the product is either illegal, unsafe, or a scam. It is none of those things by default — but the label is a real counseling moment, and the answer depends on where the product came from.

The label reflects the regulatory structure under which the bulk peptide was sold, not a direct claim about the product's quality. Bulk peptides sold through research-chemical channels are not marketed for therapeutic use, and federal labeling rules require the RUO language on that channel. A peptide dispensed through a licensed compounding pharmacy on a valid prescription generally will not carry that label — because the regulatory channel is different.

When a patient asks, the useful answer is structural, not defensive:

  • Explain which regulatory channel the product you are prescribing came through (503A compounding pharmacy, 503B outsourcing facility, or research-chemical supplier).
  • Show the Certificate of Analysis for the lot. Concrete test results land better than reassurance.
  • If the label is present, explain that it reflects how the bulk substance was sold, not a safety finding. If the label is absent, explain that it is because the product was compounded under a prescription.
  • Do not oversell. The peptide regulatory landscape has changed meaningfully in 2026 — link patients to the FDA regulatory reference for current status on any specific peptide.

A printable patient handout version of this counseling content is planned and will be linked here when available.

Starter Pack

Need Help Finding a Reputable Compounding Pharmacy Partner?

Get the starter pack. If you are actively prescribing, we can help assess your current pharmacy or route you toward vetted partners through the follow-up conversation.

Get the Starter PackRead 503A vs 503B

Frequently Asked Questions

Sourcing Questions, Handled End to End

Pair the sourcing framework with consent templates, implementation checklists, and optional pharmacy-partner guidance inside the starter pack.

Get the Starter PackRead the Regulatory Reference